• Amylyx flagged first-in-human Phase 1 LUMINA data for AMX0114 in ALS for presentation at ENCALS 2026 on June 24.
• Early readout from the lowest-dose cohort showed no drug-related serious safety issues, supporting escalation to higher doses.
• Biomarker signals held broadly steady versus baseline, leaving efficacy implications unclear at this stage.
• The randomized, placebo-controlled multiple-ascending-dose study is running in Canada and the US, with additional higher-dose cohorts underway.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amylyx Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260623249003) on June 23, 2026, and is solely responsible for the information contained therein.